CA90873/CA/NCI NIH HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
2003	2
2004	2
2005	3
2006	6
2016	1
2024	0

1

Therapeutic implications of autoimmune vitiligo T cells.

Oyarbide-Valencia K, van den Boorn JG, Denman CJ, Li M, Carlson JM, Hernandez C, Nishimura MI, Das PK, Luiten RM, Le Poole IC. Oyarbide-Valencia K, et al. Autoimmun Rev. 2006 Aug;5(7):486-92. doi: 10.1016/j.autrev.2006.03.012. Epub 2006 May 6. Autoimmun Rev. 2006. PMID: 16920575 Free PMC article. Review.

2

Redirecting T lymphocyte specificity using T cell receptor genes.

Kaplan BL, Yu DC, Clay TM, Nishimura MI. Kaplan BL, et al. Int Rev Immunol. 2003 May-Aug;22(3-4):229-53. doi: 10.1080/08830180305227. Int Rev Immunol. 2003. PMID: 12745641 Review.

3

Interferon-gamma renders tumors that express low levels of Her-2/neu sensitive to cytotoxic T cells.

Kaplan BL, Norell H, Callender GG, Ohlum T, Kiessling R, Nishimura MI. Kaplan BL, et al. Cancer Immunol Immunother. 2006 Jun;55(6):653-62. doi: 10.1007/s00262-005-0050-5. Epub 2005 Sep 6. Cancer Immunol Immunother. 2006. PMID: 16151808 Free PMC article.

4

CD4 and CD8 T-lymphocyte recognition of prostate specific antigen in granulomatous prostatitis.

Klyushnenkova EN, Ponniah S, Rodriguez A, Kodak J, Mann DL, Langerman A, Nishimura MI, Alexander RB. Klyushnenkova EN, et al. J Immunother. 2004 Mar-Apr;27(2):136-46. doi: 10.1097/00002371-200403000-00007. J Immunother. 2004. PMID: 14770085

5

Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLA-A2 restricted MART-1 T-cell receptor: a phase I trial in metastatic melanoma.

Duval L, Schmidt H, Kaltoft K, Fode K, Jensen JJ, Sorensen SM, Nishimura MI, von der Maase H. Duval L, et al. Clin Cancer Res. 2006 Feb 15;12(4):1229-36. doi: 10.1158/1078-0432.CCR-05-1485. Clin Cancer Res. 2006. PMID: 16489078 Clinical Trial.

6

Influence of human CD8 on antigen recognition by T-cell receptor-transduced cells.

Lyons GE, Moore T, Brasic N, Li M, Roszkowski JJ, Nishimura MI. Lyons GE, et al. Cancer Res. 2006 Dec 1;66(23):11455-61. doi: 10.1158/0008-5472.CAN-06-2379. Cancer Res. 2006. PMID: 17145893

7

CD8-independent tumor cell recognition is a property of the T cell receptor and not the T cell.

Roszkowski JJ, Yu DC, Rubinstein MP, McKee MD, Cole DJ, Nishimura MI. Roszkowski JJ, et al. J Immunol. 2003 Mar 1;170(5):2582-9. doi: 10.4049/jimmunol.170.5.2582. J Immunol. 2003. PMID: 12594285

8

Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor.

Roszkowski JJ, Lyons GE, Kast WM, Yee C, Van Besien K, Nishimura MI. Roszkowski JJ, et al. Cancer Res. 2005 Feb 15;65(4):1570-6. doi: 10.1158/0008-5472.CAN-04-2076. Cancer Res. 2005. PMID: 15735047

9

TCR gene-modified T cells can efficiently treat established hepatitis C-associated hepatocellular carcinoma tumors.

Spear TT, Callender GG, Roszkowski JJ, Moxley KM, Simms PE, Foley KC, Murray DC, Scurti GM, Li M, Thomas JT, Langerman A, Garrett-Mayer E, Zhang Y, Nishimura MI. Spear TT, et al. Cancer Immunol Immunother. 2016 Mar;65(3):293-304. doi: 10.1007/s00262-016-1800-2. Epub 2016 Feb 3. Cancer Immunol Immunother. 2016. PMID: 26842125 Free PMC article.

10

Identification of a hepatitis C virus-reactive T cell receptor that does not require CD8 for target cell recognition.

Callender GG, Rosen HR, Roszkowski JJ, Lyons GE, Li M, Moore T, Brasic N, McKee MD, Nishimura MI. Callender GG, et al. Hepatology. 2006 May;43(5):973-81. doi: 10.1002/hep.21157. Hepatology. 2006. PMID: 16628627

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

12 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year